| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
i
|
|
|
|
EASL Monothematic Tallin, Estonia
|
|
ii
|
|
|
|
ILC Barcelona 2012
|
|
iii
|
|
|
|
Clinical School of Hepatology Bologna
|
|
iv
|
|
|
|
Short-Term Fellowship
|
|
v
|
|
|
|
Contents
|
|
vii-ix
|
|
| Focus |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Focus
18 October 2011
Advanced hepatic fibrosis is associated with a worse prognosis in patients with chronic hepatitis C virus (HCV) infection. Cumulative clinical experience also suggests that response rates to anti-vira...
|
Daniel Shouval
|
303-304
|
|
| Editorials |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Yes! Statins can be given to liver patients
29 September 2011
Statins are given to 10–20% of adults in developed countries. Statins increase alanine aminotransferase (ALT) concentrations in 10% of patients without liver disease, and this increase can exceed more...
|
Ted Bader
|
305-307
|
|
|
|
NKG2D and its ligands: Key to immunotherapy of liver cancer?
27 July 2011
Hepatocellular carcinoma (HCC) is a common cancer accounting for a significant proportion of all cancers worldwide. Although most cases of HCC occur in countries where hepatitis B virus (HBV) and hepa...
|
Mario U. Mondelli
|
308-310
|
|
|
|
HIF-1α is a major and complex player in alcohol induced liver diseases
29 September 2011
Hepatic steatosis is one of the earliest and most consistent changes which occur with excessive consumption of alcohol. The development of steatosis is known to sensitize the liver to other insults, a...
|
Wajahat Z. Mehal
|
311-312
|
|
| Research Articles |
| Viral Hepatitis |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
23 May 2011
Background & Aims: Interferon-alfa (IFN)-related cytopenias are common and may be dose-limiting. We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to ident...
|
Alexander J. Thompson,
Paul J. Clark,
Abanish Singh,
Dongliang Ge,
Jacques Fellay,
Mingfu Zhu,
Qianqian Zhu,
Thomas J. Urban,
Keyur Patel,
Hans L. Tillmann,
Susanna Naggie,
Nezam H. Afdhal,
Ira M. Jacobson,
Rafael Esteban,
Fred Poordad,
Eric J. Lawitz,
Jonathan McCone,
Mitchell L. Shiffman,
Greg W. Galler,
John W. King,
Paul Y. Kwo,
Kevin V. Shianna,
Stephanie Noviello,
Lisa D. Pedicone,
Clifford A. Brass,
Janice K. Albrecht,
Mark S. Sulkowski,
David B. Goldstein,
John G. McHutchison,
Andrew J. Muir
et al.
|
313-319
|
|
|
|
Gaps in the achievement of effectiveness of HCV treatment in national VA practice
13 July 2011
Background & Aims: Antiviral treatment for hepatitis C virus (HCV) has high efficacy rates for achieving sustained viral response (SVR) in randomized controlled trials (RCTs) (40–80%); however, it...
|
Jennifer R. Kramer,
Fasiha Kanwal,
Peter Richardson,
Minghua Mei,
Hashem B. El-Serag
et al.
|
320-325
|
|
|
|
A functional genomic screen reveals novel host genes that mediate interferon-alpha’s effects against hepatitis C virus
02 September 2011
Background & Aims: The precise mechanisms by which IFN exerts its antiviral effect against HCV have not yet been elucidated. We sought to identify host genes that mediate the antiviral effect of I...
|
Hong Zhao,
Wenyu Lin,
Kattareeya Kumthip,
Du Cheng,
Dahlene N. Fusco,
Oliver Hofmann,
Nikolaus Jilg,
Andrew W. Tai,
Kaku Goto,
Leiliang Zhang,
Winston Hide,
Jae Young Jang,
Lee F. Peng,
Raymond T. Chung
et al.
|
326-333
|
|
|
|
A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse
13 July 2011
Background & Aims: Guidelines recommend 6months of alcohol abstinence before treating hepatitis C (HCV). Abstinence is difficult for alcohol-dependent patients to achieve. This study evaluated HCV...
|
Caroline Le Lan,
Anne Guillygomarc’h,
Hélène Danielou,
Gérard Le Dréau,
Fabrice Lainé,
Claude Védeilhié,
Yves Deugnier,
Pierre Brissot,
Dominique Guyader,
Romain Moirand
et al.
|
334-340
|
|
|
|
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis
13 July 2011
Background & Aims: The success of pegylated-interferon (PegIFN)/ribavirin (Rbv) therapy of chronic hepatitis C is compromised by liver fibrosis. Whether fibrosis equally affects the two PegIFNα-ba...
|
Gian Maria Prati,
Alessio Aghemo,
Maria Grazia Rumi,
Roberta D’Ambrosio,
Stella De Nicola,
Maria Francesca Donato,
Elisabetta Degasperi,
Massimo Colombo
et al.
|
341-347
|
|
| Cirrhosis |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study
11 July 2011
Background & Aims: Splanchnic arterial vasodilatation plays an important role in cirrhotic ascites. The aim of this study was to evaluate the effects of long term administration of midodrine on sy...
|
Virendra Singh,
Sahdeb P. Dhungana,
Baljinder Singh,
Rajesh Vijayverghia,
Chander K. Nain,
Navneet Sharma,
Ashish Bhalla,
Pramod K. Gupta
et al.
|
348-354
|
|
| Transplantation |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation
02 September 2011
Background & Aims: Recipient and donor IL28B polymorphisms seem to play an important role in the response to hepatitis C treatment after liver transplantation (LT). Since donor peripheral blood mo...
|
Mairene Coto-Llerena,
Gonzalo Crespo,
Patricia González,
George Koutsoudakis,
Rosa Miquel,
Miquel Navasa,
Xavier Forns,
Sofía Pérez-del-Pulgar
et al.
|
355-358
|
|
| Liver Failure and Growth |
| |
Article Title |
Author(s) |
Pages |
|
|
|
HO-1–STAT3 axis in mouse liver ischemia/reperfusion injury: Regulation of TLR4 innate responses through PI3K/PTEN signaling
13 July 2011
Background & Aims: Signal transducer and activator of transcription 3 (STAT3), a key mediator of anti-inflammatory cytokine signaling, is essential for heme oxygenase-1 (HO-1)-induced cytoprotecti...
|
Bibo Ke,
Xiu-Da Shen,
Haofeng Ji,
Naoko Kamo,
Feng Gao,
Maria Cecilia S. Freitas,
Ronald W. Busuttil,
Jerzy W. Kupiec-Weglinski
et al.
|
359-366
|
|
|
|
Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice
13 July 2011
Background & Aims: Bile acids (BA) are increasingly recognized as important modulators of liver regeneration. Increased enterohepatic BA flux has been proposed to generate specific signals that ac...
|
Maite G. Fernández-Barrena,
Maria J. Monte,
Maria U. Latasa,
Iker Uriarte,
Eva Vicente,
Haisul C.Y. Chang,
Carlos M. Rodriguez-Ortigosa,
Ronald Oude Elferink,
Carmen Berasain,
Jose J.G. Marin,
Jesus Prieto,
Matias A. Ávila
et al.
|
367-373
|
|
|
|
Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing
02 September 2011
Background & Aims: Limited data exist on drug-induced liver injury (DILI) associated with statins. Methods: Reports on adverse reactions suspected to be due to statins received by the Swedish Adve...
|
Einar Björnsson,
Elin I. Jacobsen,
Evangelos Kalaitzakis
|
374-380
|
|
| Cancer |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence
13 July 2011
Background & Aims: The activating receptor natural killer group 2, member D (NKG2D) and its ligands play a crucial role in immune response to tumors. NKG2D ligand expression in tumors has been sho...
|
Hiroteru Kamimura,
Satoshi Yamagiwa,
Atsunori Tsuchiya,
Masaaki Takamura,
Yasunobu Matsuda,
Shogo Ohkoshi,
Makoto Inoue,
Toshifumi Wakai,
Yoshio Shirai,
Minoru Nomoto,
Yutaka Aoyagi
et al.
|
381-388
|
|
|
|
MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma
02 September 2011
Background & Aims: Portal vein tumor thrombus (PVTT) has previously been demonstrated to correlate with poor prognosis of hepatocellular carcinoma. Approximately 50–80% of HCC is accompanied by po...
|
Shupeng Liu,
Weixing Guo,
Jie Shi,
Nan Li,
Xiya Yu,
Jie Xue,
Xiaohui Fu,
Kaijian Chu,
Chongde Lu,
Jiangsha Zhao,
Dong Xie,
Mengchao Wu,
Shuqun Cheng,
Shanrong Liu
et al.
|
389-396
|
|
|
|
The changing scenario of hepatocellular carcinoma over the last two decades in Italy
13 July 2011
Background & aims: This study investigates whether the aetiologic changes in liver disease and the improved management of hepatocellular carcinoma (HCC) have modified the clinical scenario of this...
|
Valentina Santi,
Daniela Buccione,
Antonio Di Micoli,
Gianluca Fatti,
Marta Frigerio,
Fabio Farinati,
Paolo Del Poggio,
Gianludovico Rapaccini,
Maria Anna Di Nolfo,
Luisa Benvegnù,
Marco Zoli,
Franco Borzio,
Edoardo Giovanni Giannini,
Eugenio Caturelli,
Maria Chiaramonte,
Mauro Bernardi,
Franco Trevisani
et al.
|
397-405
|
|
|
|
Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma
21 July 2011
Background & Aims: The European Association for the Study of the Liver (EASL) criteria and, more recently, the modified Response Evaluation Criteria in Solid Tumors (mRECIST), have been widely ado...
|
Ju Hyun Shim,
Han Chu Lee,
Hyung Jin Won,
Yong Moon Shin,
Kang Mo Kim,
Young-Suk Lim,
Dong Jin Suh
et al.
|
406-411
|
|
|
|
Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma
12 July 2011
Background & Aims: To compare the survival between surgical resection (SR) and radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC)...
|
Jing-Houng Wang,
Chih-Chi Wang,
Chao-Hung Hung,
Chao-Long Chen,
Sheng-Nan Lu
et al.
|
412-418
|
|
|
|
Inducible and repressable oncogene-addicted hepatocellular carcinoma in Tet-on xmrk transgenic zebrafish
02 September 2011
Background & Aims: Liver cancer, mainly hepatocellular carcinoma, is a major malignancy and currently there are no effective treatment protocols due to insufficient understanding of hepatocarcinog...
|
Zhen Li,
Xiaoqian Huang,
Huiqing Zhan,
Zhiqiang Zeng,
Caixia Li,
Jan M. Spitsbergen,
Svenja Meierjohann,
Manfred Schartl,
Zhiyuan Gong
et al.
|
419-425
|
|
|
|
A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis
08 September 2011
Background & Aims: Genetic dimorphisms modulate the activities of several pro- or antioxidant enzymes, including myeloperoxidase (MPO), catalase (CAT), manganese superoxide dismutase (SOD2), and g...
|
Pierre Nahon,
Angela Sutton,
Pierre Rufat,
Nathalie Charnaux,
Abdellah Mansouri,
Richard Moreau,
Nathalie Ganne-Carrié,
Véronique Grando-Lemaire,
Gisèle N’Kontchou,
Jean-Claude Trinchet,
Dominique Pessayre,
Michel Beaugrand
et al.
|
426-432
|
|
| Genetic and Metabolic Diseases |
| |
Article Title |
Author(s) |
Pages |
|
|
|
High fructose feeding induces copper deficiency in Sprague–Dawley rats: A novel mechanism for obesity related fatty liver
20 July 2011
Background & Aims: Dietary copper deficiency is associated with a variety of manifestations of the metabolic syndrome, including hyperlipidemia and fatty liver. Fructose feeding has been reported ...
|
Ming Song,
Dale A. Schuschke,
Zhanxiang Zhou,
Theresa Chen,
William M. Pierce,
Renwei Wang,
W. Thomas Johnson,
Craig J. McClain
et al.
|
433-440
|
|
|
|
HIF-1α induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice
07 September 2011
Background & Aims: Chronic alcohol intake stimulates hepatic oxygen consumption and subsequently causes liver hypoxia, leading to activation of hypoxia inducible factor-1 (HIF-1). Although HIF-1 p...
|
Yasumasa Nishiyama,
Nobuhito Goda,
Mai Kanai,
Daisuke Niwa,
Kota Osanai,
Yu Yamamoto,
Nanami Senoo-Matsuda,
Randall S. Johnson,
Soichiro Miura,
Yasuaki Kabe,
Makoto Suematsu
et al.
|
441-447
|
|
|
|
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies
13 July 2011
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a complex disease trait where genetic variations and environment interact to determine disease progression. The association of PNPLA...
|
Ahmad Al-Serri,
Quentin M. Anstee,
Luca Valenti,
Valerio Nobili,
Julian B.S. Leathart,
Paola Dongiovanni,
Julia Patch,
Anna Fracanzani,
Silvia Fargion,
Christopher P. Day,
Ann K. Daly
et al.
|
448-454
|
|
| Reviews |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals
30 August 2011
Summary: Dermatological adverse events (AEs) are an existing concern during hepatitis C virus (HCV) infection and peginterferon/ribavirin treatment. HCV infection leads to dermatological and muco-cuta...
|
Patrice Cacoub,
Marc Bourlière,
Jann Lübbe,
Nicolas Dupin,
Peter Buggisch,
Geoffrey Dusheiko,
Christophe Hézode,
Odile Picard,
Ramon Pujol,
Siegfried Segaert,
Bing Thio,
Jean-Claude Roujeau
et al.
|
455-463
|
|
|
|
Radioembolization for hepatocellular carcinoma
03 August 2011
Summary: Radioembolization is a form of brachytherapy in which intra-arterially injected 90Y-loaded microspheres serve as sources for internal radiation purposes. It produces average disease control r...
|
Bruno Sangro,
Mercedes Iñarrairaegui,
Jose I. Bilbao
|
464-473
|
|
| Special Sections |
| Frontiers in Liver Transplantation |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Liver transplantation using Donation after Cardiac Death donors
22 July 2011
Summary: The success of solid organ transplantation has brought about burgeoning waiting lists with insufficient donation rates and substantial waiting list mortality. All countries have strived to ex...
|
Diethard Monbaliu,
Jacques Pirenne,
David Talbot
|
474-485
|
|
| International Hepatology |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
29 September 2011
COMMENTARY ON:: Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R...
|
Jairo A. Garcia,
Lewis R. Roberts
|
486-487
|
|
|
|
Back to basics: Staging and prognosis in HCC for medical oncologist
27 July 2011
COMMENTARY ON:: Advanced hepatocellular carcinoma: which staging systems best predict prognosis? Huitzil-Melendez FD, Capanu M, O’Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK. J Clin Oncol 20...
|
Markus Peck-Radosavljevic
|
488-489
|
|
|
|
EpCAM in hepatocytes and their progenitors
27 July 2011
COMMENTARY ON:: Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans. Yoon SM, Gerasimidou D, Kuwahara R, Hytiroglou P, Yoo JE, Park YN, Theis...
|
Olivier Gires
|
490-492
|
|
| Hepatology Snapshot |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Chimeric mouse model of hepatitis B virus infection
27 July 2011
Chronic infection with hepatitis B virus (HBV) continues to be a major health problem affecting about 400 million people worldwide. The narrow species tropism of HBV has hindered progresses in HBV res...
|
Maura Dandri,
Jörg Petersen
|
493-495
|
|
| Clinical Application of Basic Science |
| |
Article Title |
Author(s) |
Pages |
|
|
|
New horizons for stem cell therapy in liver disease
27 July 2011
Summary: There is an increasing range of potential applications of stem cells in liver diseases, with many clinical studies already undertaken. We identify four of the main areas which we propose stem...
|
Stuart J. Forbes,
Philip N. Newsome
|
496-499
|
|
| Case Report |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient
27 July 2011
Abstract: Acute hepatitis E virus (HEV) infection is a self-limiting symptomatic or asymptomatic disease. However, as recently observed, it can manifest itself as chronic hepatitis in patients receivi...
|
B. Schlosser,
A. Stein,
R. Neuhaus,
S. Pahl,
B. Ramez,
D.H. Krüger,
T. Berg,
J. Hofmann
et al.
|
500-502
|
|
| Letters to the Editor |
| |
Article Title |
Author(s) |
Pages |
|
|
|
The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice
29 June 2011
The excitement about the new standard of care for the treatment of chronic hepatitis C virus (HCV) infection is warranted given the dramatically increased rates of sustained virologic response achieve...
|
Jeffrey J. Weiss,
Marlene C. Alcorn,
Judith G. Rabkin,
Douglas T. Dieterich
|
503-504
|
|
|
|
Herbal medicine hepatotoxicity revisited
22 July 2011
In the April 2011 issue of the Journal of Hepatology, an editorial discussed hepatotoxicity associated with the use of herbal preparations . The focus of the article is primarily on the need to develo...
|
Kristy Appelhans,
Vasilios Frankos
|
504-505
|
|
|
|
Reply to: “Herbal medicine hepatotoxicity revisited”
18 July 2011
The author’s letter states that the mention of some instances of herbal medicines is immaterial in the context of the article’s discussion. We do not agree with this view for the following reasons.
|
Dominique Larrey,
Stéphanie Faure
|
505
|
|
|
|
Ammonia and cerebral water. Importance of structural analysis of the brain in hepatic encephalopathy
15 July 2011
We read with interest the article by Mardini and colleagues , who induced hyperammonaemia experimentally in patients with cirrhosis. They show an increase in apparent diffusion coefficient (ADC) repor...
|
Mark J.W. McPhail,
Novraj S. Dhanjal,
Vijay P. Grover,
Simon D. Taylor-Robinson
|
506
|
|
|
|
Reply to: “Ammonia and cerebral water. Importance of structural analysis of the brain in hepatic encephalopathy”
22 July 2011
We thank McPhail et al. for their comments regarding our paper in which we reported that induced hyperammonaemia in patients with hepatic encephalopathy (HE) leads to a transient increase in brain wa...
|
Fiona Elizabeth Smith,
Hanan Mardini,
Christopher O. Record,
Andrew M. Blamire
|
506-507
|
|
|
|
C reactive protein levels in non-alcoholic fatty liver disease
02 September 2011
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. It represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign...
|
Teoman Dogru,
Halil Genc,
Sait Bagci
|
507-508
|
|
|
|
Reply to: “C-reactive protein levels in non-alcoholic fatty liver disease”
31 August 2011
We thank Dr. Dogru et al. for their comments on our paper on C-reactive protein (CRP) levels in relation to various features of non-alcoholic fatty liver disease (NAFLD) among obese patients . In our ...
|
Tine Jess,
Esther Zimmermann,
Rodolphe Anty,
Joan Tordjman,
An Verrijken,
Philippe Gual,
Albert Tran,
Antonio Iannelli,
Jean Gugenheim,
Pierre Bedosa,
Sven Francque,
Yannick Le Marchand-Brustel,
Karine Clement,
Luc Van Gaal,
Thorkild I.A. Sørensen
et al.
|
508-510
|
|
